Focused on Cures
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients
INNOVATIVE
Technology
Excision's cutting edge CRISPR gene therapy platform is built on technology licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.
We are the first company to remove HIV genomes from animals and generate functional cures for HIV.
NOVEL
Approach
SAFE
Targets non-human viral genomes minimizing chance of off-target cuts
EFFICIENT
Excision products require one-time gene edit to remove the viral genome permanently
“I am optimistic that Excision’s technology and approach using CRISPR could potentially cure infectious diseases and bring much needed therapies to those in need around the world.”
Jennifer Doudna, Ph.D., CRISPR Co-inventor
UC Berkeley, 2020
OUR
Partners
499 Jackson Street
San Francisco, CA 94111
USA
